Ting Cheng: Why Gene Therapy Needs Reinvention Before It Can Reach Millions
Ting Cheng, Principal Scientist at Johnson & Johnson, AI/Tech and Pharma/Healthcare Investor, shared on LinkedIn:
”Pfizer approved a hemophilia gene therapy in 2025.
Then pulled it — because not a single patient ever received it after approval.
In that same seven-month window, five major pharma companies spent over $10 billion acquiring pre-commercial cell therapy companies, before any of them had treated a paying patient.
Both things are true at once, and the article breaks down what that actually means: the current generation’s manufacturing and pricing model is broken, not the underlying biology — which already has 34,000 treated patients and 14 billion USD in 2024 revenue behind five approved drugs.
The next wave is targeting something structurally different — a $150 billion market the current approach was never built to reach.
Read the full breakdown here.”
Stay updated with Hemostasis Today.
-
Jul 29, 2026, 16:30Mostafa Faisal: Impact of DNMT3A and TET2 Mutations on Clotting and Bleeding in PV and ET
-
Jul 29, 2026, 16:01Gerardo Moscatelli: The Spike Protein Cascade – From Endothelial Binding to Vascular Collapse
-
Jul 29, 2026, 15:42Julie Cardoso: FDA Clears the First AI-Guided Ultrasound Software for Suspected DVT
-
Jul 29, 2026, 15:26Ahmad Alkhammash: Completing an Advanced Fellowship in Adult Thrombosis Medicine
-
Jul 29, 2026, 15:13Yara Mahmoud: The Molecular Basis in Hematology
-
Jul 29, 2026, 15:11Louisa Jorm: A New Era of Dynamic Cardiovascular Risk Assessment
-
Jul 29, 2026, 15:04Filippo Consonni: Treatment Strategies for Hematologic Immune Dysregulation in Inborn Errors of Immunity
-
Jul 29, 2026, 14:53Samer Alsaid: Warfarin Outcomes Reassessed Through COMBINE AF
-
Jul 29, 2026, 14:46François Saller: TFPI-Targeting VHHs for Haemophilia and Rare Bleeding Disorders